Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and
agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one
of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morni...
Age: 65 years - 66+
Gender: All
Palliative Care for Patients With Dementia
A multi-site, single-blinded, parallel, randomized-controlled trial to evaluate the
effectiveness of a novel model of in-home palliative care for dementia patients and their
family caregivers. From inpatient and outpatient settings associated with four hospitals
a...
Age: 65 years - 66+
Gender: All
Alzheimer's Disease Neuroimaging Initiative 4
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical
trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies...
Age: 55 - 90 years
Gender: All
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019...
Age: 18 years - 66+
Gender: All
Hyperbaric Oxygen Therapy for Cognition in Diabetic Elderly at High Dementia Risk
An urgent need exists to identify effective interventions to arrest or reverse dementia and
cognitive loss at its earliest stages. The proposed pilot randomized clinical trial will
investigate the short and long-term effects of hyperbaric oxygen therapy on cognitive...
Age: 65 years - 66+
Gender: All
An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive
decline compared with placebo treatment, as measured by a composite cognitive measure, the
Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants w...
Age: 60 - 85 years
Gender: All
Methodology Issues in a Tailored Light Treatment for Persons With Dementia
Tailored light treatment will increase sleep efficiency, reduce depression and reduce
agitation scores in those with Alzheimer's disease and related dementia
Age: 65 years - 66+
Gender: All